Gastric Adenocarcinoma Clinical Trials in Chicago, Illinois

3 studies are recruiting for gastric adenocarcinoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

   This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitax…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   78 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT07001748 on ClinicalTrials.gov

2. AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

   This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago, Chicago, Illinois

   Locations

   7 in total

   Run by

   Avacta Life Sciences Ltd

   See if you can join NCT07454642 on ClinicalTrials.gov

3. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

   Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tel…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   46 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT05365581 on ClinicalTrials.gov